Publications
2007
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Hantschel O,
Rix U,
Schmidt U,
Burckstummer T,
Kneidinger M,
Schutze G,
Colinge J,
Bennett KL,
Ellmeier W,
Valent P,
Superti-Furga G.
Proc Natl Acad Sci USA. 2007, 104:13283–13288.
